Strengthens Lyell’s clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidateData from ImmPACT’s ...

Weill Cornell Medicine researchers have discovered a mechanism that ovarian tumors use to cripple immune cells and impede their attack - blocking the ...

Researchers at Weill Cornell Medicine have shown that ovarian cancers disable immune cells and prevent them from attacking by ...

Both agreed that there have been no trials directly comparing a BsAb therapy vs CAR T cells, so there is no definitive answer, and Landsburg was reluctant to take a hard line on reserving BsAbs until ...

Weill Cornell Medicine researchers have discovered a mechanism that ovarian tumors use to cripple immune cells and impede ...

INT2104 is a novel in vivo chimeric antigen receptor (CAR) gene therapy designed to generate CAR-T and CAR-NK cells in the patient’s body to target CD20 ... Michael Dickinson, MBBS, FRACP, Lead of the ...

"CAR T cells work well against hematological cancers like leukemia and lymphoma, but they're really not effective for solid tumors ... in ovarian cancer and suggest new avenues to improve the efficacy ...

Lymphoma, a cancer of the immune system, is silently ravaging the health of Black men across America. This insidious disease, ...

Jenna Cottrell is a young sports reporter working for a TV station in the Rochester, N.Y., area. She's also a survi ...

Three months after the CAR-T cell infusion, the CR rate was 87.5% (7 out of 8). Notably, one patient with leukemia showed a CR with no minimal residual disease (MRD), while another patient with ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

During a Case-Based Roundtable® event, Andrew H. Lipsky, MD, moderated a discussion on the efficacy and safety of newer BTK ...